# 503193015 02/24/2015

# PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT3239632

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

#### **CONVEYING PARTY DATA**

Name	Execution Date
TAKEDA PHARMACEUTICAL COMPANY LIMITED	12/15/2014

### **RECEIVING PARTY DATA**

Name:	INTRA-CELLULAR THERAPIES, INC.
Street Address:	3960 BROADWAY
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10032

# **PROPERTY NUMBERS Total: 2**

Property Type	Number
Application Number:	13552381
Application Number:	11916761

#### **CORRESPONDENCE DATA**

**Fax Number:** (973)912-5236

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

**Phone:** 9739125232

Email: hoxiepatentmail@hoxpat.com
Correspondent Name: HOXIE & ASSOCIATES, LLC

Address Line 1: 75 MAIN STREET

Address Line 2: SUITE 203

Address Line 4: MILLBURN, NEW JERSEY 07041

ATTORNEY DOCKET NUMBER:	IT-01-USD1 AND IT-01-US
NAME OF SUBMITTER:	BRITTANY LA
SIGNATURE:	/Brittany La/
DATE SIGNED:	02/24/2015

#### **Total Attachments: 7**

source=IT-01 - assignment from Takeda to ITI - Takeda executed#page1.tif source=IT-01 - assignment from Takeda to ITI - Takeda executed#page2.tif source=IT-01 - assignment from Takeda to ITI - Takeda executed#page3.tif source=IT-01 - assignment from Takeda to ITI - Takeda executed#page4.tif

PATENT 503193015 REEL: 035020 FRAME: 0420

source=IT-01 - assignment from Takeda to ITI - Takeda executed#page5.tif
source=IT-01 - assignment from Takeda to ITI - Takeda executed#page6.tif
source=IT-01 - assignment from Takeda to ITI - Takeda executed#page7.tif

#### ASSIGNMENT

WHEREAS, Takeda Pharmaceutical Company Limited, a Japanese company having a place of business at 1-1, Doshomachi 4-Chome, Chuo-ku, Osaka 541-0045, Japan ("Takeda"), hereinafter referred to as ASSIGNOR, owns the entire right, title and interest in the inventions and/or improvements entitled:

#### **ORGANIC COMPOUNDS**

for which International Application No. PCT/US2006/022066 was filed on June 6, 2006, and a U.S. Provisional application was filed on June 6, 2005, as U.S. Patent Application No. 60/687,715, wherein further Applications for Letters Patent have been filed, which patent applications are listed in Exhibit A (hereinafter "ASSIGNED PATENT APPLICATIONS"); and

WHEREAS, Intra-Cellular Therapies, Inc., a corporation organized and existing under and by virtue of the laws of the State of Delaware, and having an office and place of business at 3960 Broadway, New York, NY 10032 ("ITI"), (hereinafter referred to as ASSIGNEE), is desirous of securing the entire right, title, and interest in and to the aforesaid invention and/or any improvements thereon in all countries throughout the world, and in and to the ASSIGNED PATENT APPLICATIONS for Letters Patent on the aforesaid invention and/or any improvements thereon and the Letters Patent to be issued upon any of the aforesaid ASSIGNED PATENT APPLICATIONS;

NOW, THEREFORE, pursuant to the License and Collaboration Agreement between ITI and Takeda, dated February 25, 2011 and the Termination Agreement between ITI and Takeda dated October 31, 2014, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, ASSIGNOR, by these presents does hereby sell, assign and transfer to ASSIGNEE, its successors and assigns, the full and exclusive right, title and interest in and to the aforesaid invention and any improvements thereon, the aforesaid ASSIGNED PATENT APPLICATIONS and all corresponding and/or counterpart foreign patent applications, all divisional, continuation, continuation-in-part, reissue, reexamination, extension, substitution, registration, renewal, patent term extension, Supplementary Protection Certificates or the like, and any additional patent applications which claim priority to any of the aforesaid ASSIGNED PATENT APPLICATIONS, and all Letters Patent or comparable rights issuing thereon in the United States and in all foreign countries, and all applications for Letters Patent which may hereafter be filed for the aforesaid invention and/or any improvements thereon in the United States and/or in any foreign country and all Letters Patent which may be granted on the aforesaid invention and/or any improvements thereon in the United States and/or in any foreign country, together with the right(s) to claim priority under the provisions of any of the international conventions, unions, agreements, acts, and treaties, including all future conventions, unions, agreements, acts, and treaties, to any of the aforesaid ASSIGNED PATENT APPLICATIONS and/or any improvements thereon, and the ASSIGNOR hereby authorize and request the United States Commissioner of Patents and Trademarks and any official of any foreign country whose duty it is to issue patents on applications as described above, to issue all Letters Patent or comparable rights issuing on any application as aforesaid to ASSIGNEE, or to its successors, assigns or legal representatives;

(Sheet 1 of 5)



ASSIGNOR hereby covenants that ASSIGNOR have full right to convey the entire interest herein assigned, and that ASSIGNOR has not executed, and will not execute, any agreement in conflict herewith;

ASSIGNOR agrees to communicate to ASSIGNEE or to its successors, assigns or legal representatives any and all facts known to them or any of them respecting said invention, and without further remuneration to testify in any legal proceeding, sign all lawful papers, execute all divisional, continuation, continuation-in-part, reissue and reexamination applications, make all rightful oaths and generally do all lawful acts to aid ASSIGNEE or its successors, assigns or legal representatives to obtain and enforce proper patent protection for said invention in all countries and to enhance or perfect ASSIGNEE's title in and to the invention and patent rights therein.

ASSIGNOR hereby authorizes attorneys for ASSIGNEE to enter on this document any applicable serial numbers and filing dates after ASSIGNOR's execution of this document.

This Assignment may be executed in one (1) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

(Sheet 2 of 5)



# EXHIBIT A

COUNTRY	APPLICATION NO.
AU	2006255028
BR	PI06110959
CA	2611312
CN	200680026973.6
CN	201310250723.2
EP	06772397.3
HK	08107460.8
IN	9296DELNP2007
IN	7677DELNP2014
JP	2008515858
JP	2012116786
JP	2014184489
KR	1020087000132
KR	1020147002847
МО	J001208
мх	MXa2007015356
wo	PCTUS0622066
US	11916761
US	13552381
	~

(Sheet 3 of 5)



	Name: Yoichi Okumura Title: General Manager, Intellectual Property Department, Takeda Pharmaceutical Company Limited Authorized Representative of Assignor
Vitnessed by:	
	Name: Izumi SHIMIZU
Vitnessed by:	
	Name: REGINA LEVESQUE
nd for the State and County	f 20, before me, a Notary Public in aforesaid, personally appeared the above signatory, known to me to who executed the foregoing instrument in my presence.

PATENT REEL: 035020 FRAME: 0425

(Sheet 4 of 5)



The ASSIGNEE hereby at IN TESTIMONY WHEREOF, I h	cknowledges and accepts this Patent Assignment from Takeda. Hereunto set pay hand and seal this
December 2014	Name: Lawrence P. Wennogle Title: Vice President, Drug Discovery, Intra-Cellular Therapies, Inc.
Witnessed by:	Authorized Representative of Assignee
	Name: ALLEN FIENBENG
Witnessed by:	A. Leeund
	Name: PAVEL GENKIN
and for the State and County afore	20 / before me, a Notary Public in said, personally appeared the above signatory, known to me to ecuted the foregoing instrument in my presence.
	1 0

(Sheet 5 of 5)





嘱託人武田薬品工業株式会社知的財産部長奥村洋一の代理人清水泉 は、本公証人に対し、同嘱託人が別紙証書の署名につき、自らしたもの であることを承認している旨陳述した。

以上


よって、これを認証する。

平成26年 12月16 日、本公証人役場において

藤沢市鵠沼石上2丁目11番2号

横浜地方法務局所属

公 証 人 Notary




DAISABURO SOGA

証

明

上記署名は、横浜地方法務局所属公証人の署名に相違ないものであり、かつ、その押印は、 真実のものであることを証明する。

平成26年 12 月 16 日



## **APOSTILLE**

(Convention de La Haye du 5 octobre 1961)

- 1. Country: JAPAN
  - This public document
- DAISABURO SOGA 2. has been signed by
- 3. acting in the capacity of Notary of the Yokohama District Legal Affairs Bureau
- 4. bears the seal/stamp of DAISABURO SOGA, Notary

Certified

5. at Tokyo

- DEC, 16,2014
- 7. by the Ministry of Foreign Affairs
- 8. 14- Nº 303142
- 9. Seal/stamp:

10.Signature:



A. Ogana

Ayako OGAWA

For the Minister for Foreign Affairs

PATENT

REEL: 035020 FRAME: 0427



Registered No. 2 5 9

# NOTARIAL CERTIFICATE

This is to certify that Izumi Shimizu, an agent of Yoichi OKUMURA, General Manager, Intellectual Property Department of Takeda Pharmaceutical Company Limited, has stated in my very presence that said Yoichi OKUMURA has acknowledged himself that the signature on the attached document is his own.

Dated this 16th day of December, 2014.

YOKOHAMA DISTRICT LEGAL AFFAIRS BUREAU IN OTA RE 2-11-2, KUGENUMAISHIGAMI FUJISAWA-SHI, KANAGAWA-KEN JAPAN

Daisabure Toga

Daisaburo Soga

Notary

attached to the Yokohama District Legal

Affairs Bureau

2-11-2 Kugenumalshigami, Fujisawa-shi

Kanagawa-ken Japan

PATENT REEL: 035020 FRAME: 0428

RECORDED: 02/24/2015